{"DataElement":{"publicId":"7482930","version":"1","preferredName":"Vasopressor Administered Therapeutic Procedure Type","preferredDefinition":"A description of the vasopressor administered therapeutic procedure type.","longName":"5227093v1.0:7482924v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5227093","version":"1","preferredName":"Vasopressor Administered","preferredDefinition":"Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure._The act of having given something (e.g., a medication or test).","longName":"5227091v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5227091","version":"1","preferredName":"Vasopressor","preferredDefinition":"Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure.","longName":"C126567","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasopressor","conceptCode":"C126567","definition":"Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"30C7442C-359C-C93B-E050-BB89AD43091E","latestVersionIndicator":"Yes","beginDate":"2016-04-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-18","modifiedBy":"ONEDATA","dateModified":"2016-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"30C7442C-35AA-C93B-E050-BB89AD43091E","latestVersionIndicator":"Yes","beginDate":"2016-04-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-18","modifiedBy":"NYCHM","dateModified":"2016-07-25","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7482924","version":"1","preferredName":"Vasopressor Therapeutic Procedure Type","preferredDefinition":"Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Something distinguishable as an identifiable class based on common qualities.","longName":"7482924v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other Vasopressor","ValueMeaning":{"publicId":"7482925","version":"1","preferredName":"Other Vasopressor","longName":"7482925","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vasopressor","conceptCode":"C126567","definition":"Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2AE3781-DD9F-21FB-E053-4EBD850AF61B","latestVersionIndicator":"Yes","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2AE3781-DDB8-21FB-E053-4EBD850AF61B","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","deletedIndicator":"No"},{"value":"Vasopressin","valueDescription":"Argipressin","ValueMeaning":{"publicId":"7482927","version":"1","preferredName":"Argipressin","longName":"7482927","preferredDefinition":"A synthetic peptide identical to the endogenous nonapeptide hormone with antidiuretic property. Synthesized in the hypothalamus and stored/released from the posterior lobe of the pituitary, argipressin's primary function is regulating extracellular fluid volume. This agent can also act as a vasoconstrictor, increasing blood pressure and systemic vascular resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Argipressin","conceptCode":"C926","definition":"A synthetic peptide identical to the endogenous nonapeptide hormone with antidiuretic property. Synthesized in the hypothalamus and stored/released from the posterior lobe of the pituitary, argipressin's primary function is regulating extracellular fluid volume. This agent can also act as a vasoconstrictor, increasing blood pressure and systemic vascular resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2AE3781-DDC5-21FB-E053-4EBD850AF61B","latestVersionIndicator":"Yes","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2AE3781-DDDE-21FB-E053-4EBD850AF61B","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","deletedIndicator":"No"},{"value":"Dopamine","valueDescription":"Dopamine","ValueMeaning":{"publicId":"7482929","version":"1","preferredName":"Dopamine","longName":"7482929","preferredDefinition":"A monoamine compound with positive inotropic activity. Dopamine is a naturally occurring catecholamine formed by decarboxylation of dehydroxyphenylalanine and a precursor of norepinephrine and epinephrine. Dopamine binds to alpha-1 and beta-1 adrenergic receptors. Mediated through myocardial beta-1 adrenergic receptors, dopamine increase heart rate and force, thereby increasing cardiac output. Alpha-1 adrenergic receptor stimulation on vascular smooth muscle, leads to vasoconstriction and results in an increase in systemic vascular resistance. Stimulation of dopaminergic receptors in renal vasculature, leads to renal blood vessel dilation, and an increase in glomerular filtration rate, renal blood flow, sodium excretion, and urine output.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dopamine","conceptCode":"C62025","definition":"A monoamine compound with positive inotropic activity. Dopamine is a naturally occurring catecholamine formed by decarboxylation of dehydroxyphenylalanine and a precursor of norepinephrine and epinephrine. Dopamine binds to alpha-1 and beta-1 adrenergic receptors. Mediated through myocardial beta-1 adrenergic receptors, dopamine increase heart rate and force, thereby increasing cardiac output. Alpha-1 adrenergic receptor stimulation on vascular smooth muscle, leads to vasoconstriction and results in an increase in systemic vascular resistance. Stimulation of dopaminergic receptors in renal vasculature, leads to renal blood vessel dilation, and an increase in glomerular filtration rate, renal blood flow, sodium excretion, and urine output.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2AE3781-DDEB-21FB-E053-4EBD850AF61B","latestVersionIndicator":"Yes","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2AE3781-DE04-21FB-E053-4EBD850AF61B","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","deletedIndicator":"No"},{"value":"Epinephrine","valueDescription":"Epinephrine","ValueMeaning":{"publicId":"2576816","version":"1","preferredName":"Epinephrine","longName":"2576816","preferredDefinition":"The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epinephrine","conceptCode":"C2292","definition":"The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2AE3781-DE0E-21FB-E053-4EBD850AF61B","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","deletedIndicator":"No"},{"value":"Norepinephrine","valueDescription":"Norepinephrine","ValueMeaning":{"publicId":"3335134","version":"1","preferredName":"Norepinephrine","longName":"3335134","preferredDefinition":"A synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrine. Norepinephrine acts directly on the alpha- and beta-adrenergic receptors. Clinically, norepinephrine is used as a peripheral vasoconstrictor that causes constriction of arterial and venous beds via its alpha-adrenergic action. It is also used as a potent inotropic and chronotropic stimulator of the heart mediated through its beta-1 adrenergic action.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Norepinephrine, DL-","conceptCode":"C62098","definition":"A synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrine. Norepinephrine acts directly on the alpha- and beta-adrenergic receptors. Clinically, norepinephrine is used as a peripheral vasoconstrictor that causes constriction of arterial and venous beds via its alpha-adrenergic action. It is also used as a potent inotropic and chronotropic stimulator of the heart mediated through its beta-1 adrenergic action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ECC4-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2AE3781-DE18-21FB-E053-4EBD850AF61B","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","deletedIndicator":"No"},{"value":"Phenylephrine","valueDescription":"Phenylephrine","ValueMeaning":{"publicId":"7060518","version":"1","preferredName":"Phenylephrine","longName":"7060518","preferredDefinition":"A direct-acting sympathomimetic amine chemically related to adrenaline and ephedrine with potent vasoconstrictor property. Phenylephrine is a post-synaptic alpha-adrenergic receptor agonist that causes vasoconstriction, increases systolic/diastolic pressures, reflex bradycardia, and stroke output.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenylephrine","conceptCode":"C62067","definition":"A direct-acting sympathomimetic amine chemically related to adrenaline and ephedrine with potent vasoconstrictor property. Phenylephrine is a post-synaptic alpha-adrenergic receptor agonist that causes vasoconstriction, increases systolic/diastolic pressures, reflex bradycardia, and stroke output.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6921-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2AE3781-DE22-21FB-E053-4EBD850AF61B","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7482923","version":"1","preferredName":"Vasopressor Therapeutic Procedure Type","preferredDefinition":"Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Something distinguishable as an identifiable class based on common qualities.","longName":"C126567:C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasopressor","conceptCode":"C126567","definition":"Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2AE3781-DD75-21FB-E053-4EBD850AF61B","latestVersionIndicator":"Yes","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2AE3781-DD86-21FB-E053-4EBD850AF61B","latestVersionIndicator":"Yes","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"MALUMK","dateModified":"2021-01-28","changeDescription":"Released. 01/28/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"CPST_TOX_vasopressor_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the vasopressor admi","type":"Preferred Question Text","description":"What was the vasopressor administered therapeutic procedure type?","url":null,"context":"NHLBI"},{"name":"Specify the vasopressor(s) used","type":"Application Standard Question Text","description":"Specify the vasopressor(s) used","url":null,"context":"NHLBI"},{"name":"Specify the vasopressor(s) used","type":"Alternate Question Text","description":"Specify the vasopressor(s) used","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2AE4062-2306-266B-E053-4EBD850AB8C4","latestVersionIndicator":"Yes","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"MALUMK","dateModified":"2021-01-28","changeDescription":"Released. 01/28/2021 KMM; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}